Design Therapeutics (DSGN) Change in Cash (2020 - 2026)
Design Therapeutics' (DSGN) quarterly Change in Cash came in at -$4.1 million in Q1 2026, up 54.07% year-on-year from -$2.7 million in Q1 2025, and down 331.11% quarter-over-quarter from $1.8 million in Q4 2025.
Design Therapeutics (DSGN) Change in Cash (2020 - 2026) Analysis & Trends
Design Therapeutics has disclosed Change in Cash across 7 years of filings, most recently posting -$4.1 million for Q1 2026.
- Change in Cash for Q1 2026 came in at -$4.1 million, up 54.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$897000.0 (up 94.3% YoY), and the FY2025 annual result was -$5.7 million, down 518.71% from the prior year.
- Change in Cash came in at -$4.1 million for Q1 2026 at Design Therapeutics, down from $1.8 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $16.3 million in Q2 2024 to a low of -$167.7 million in Q2 2022.
- The 5-year median for Change in Cash is -$4.6 million (2025), against an average of -$16.8 million.
- Peak annual rise in Change in Cash reached 1111.29% in 2024, while the deepest fall reached 2163.22% in 2024.
- Design Therapeutics' Change in Cash stood at -$16.0 million in 2022, then soared by 57.91% to -$6.7 million in 2023, then decreased by 15.17% to -$7.8 million in 2024, then surged by 122.77% to $1.8 million in 2025, then plunged by 331.11% to -$4.1 million in 2026.
- The last three Change in Cash figures came in at -$4.1 million (Q1 2026), $1.8 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 623.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 417.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -45.97 Mn |
| 10 | Design Therapeutics | 763.94 Mn | 541.11 Mn | - | -4.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.09 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Sep 30, 2025 | -4.62 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | -8.90 Mn |
| Dec 31, 2024 | -7.77 Mn |
| Sep 30, 2024 | -15.37 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Mar 31, 2024 | 8.20 Mn |
| Dec 31, 2023 | -6.74 Mn |
| Sep 30, 2023 | 745,000.00 |
| Jun 30, 2023 | -1.61 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | -16.02 Mn |
| Sep 30, 2022 | -77.14 Mn |
| Jun 30, 2022 | -167.66 Mn |
| Mar 31, 2022 | -11.26 Mn |
| Dec 31, 2021 | -59.09 Mn |
| Sep 30, 2021 | -13.18 Mn |
| Jun 30, 2021 | -29.86 Mn |